O6 - Patient-reported outcomes (PROs) From TITAN: A phase 3, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)

Autor: Agarwal, N., Mcquarrie, K., Bjartell, A., Chowdhury, S., Pereira De Santana Gomes, A.J., Chung, B.H., Özgüroğlu, M., Juárez Soto, Á., Merseburger, A.S., Uemura, H., Ye, D-W., Given, R., Miladinovic, B., Dearden, L., Deprince, K., Naini, V., Lopez-Gitlitz, A., Chi, K.N.
Zdroj: In European Urology Supplements November 2019 18(11):e3413-e3414
Databáze: ScienceDirect
Externí odkaz: